(Q41662682)

English

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine

scientific article published on 13 November 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 October 2017

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine (English)

1 reference

Europe PubMed Central

6 October 2017

1 reference

based on heuristic

inferred from title

pneumococcal conjugate vaccine

1 reference

based on heuristic

inferred from title

William C. Gruber

12

object named as

William C Gruber

1 reference

Europe PubMed Central

6 October 2017

author name string

Marshall J Glesby

1

1 reference

Europe PubMed Central

6 October 2017

Wendy Watson

2

1 reference

Europe PubMed Central

6 October 2017

Cynthia Brinson

3

1 reference

Europe PubMed Central

6 October 2017

Richard N Greenberg

4

1 reference

Europe PubMed Central

6 October 2017

Jacob P Lalezari

5

1 reference

Europe PubMed Central

6 October 2017

Daniel Skiest

6

1 reference

Europe PubMed Central

6 October 2017

Vani Sundaraiyer

7

1 reference

Europe PubMed Central

6 October 2017

Robert Natuk

8

1 reference

Europe PubMed Central

6 October 2017

Alejandra Gurtman

9

1 reference

Europe PubMed Central

6 October 2017

Daniel A Scott

10

1 reference

Europe PubMed Central

6 October 2017

Emilio A Emini

11

1 reference

Europe PubMed Central

6 October 2017

Beate Schmoele-Thoma

13

1 reference

Europe PubMed Central

6 October 2017

language of work or name

0 references

publication date

13 November 2014

1 reference

Europe PubMed Central

6 October 2017

Journal of Infectious Diseases

1 reference

Europe PubMed Central

6 October 2017

212

1 reference

Europe PubMed Central

6 October 2017

1

1 reference

Europe PubMed Central

6 October 2017

18-27

1 reference

Europe PubMed Central

6 October 2017

The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Invasive pneumococcal disease among HIV-positive individuals, 2000-2009.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

HIV and influenza virus infections are associated with increased blood pneumococcal load: a prospective, hospital-based observational study in South Africa, 2009-2011.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Immunization against pneumococcal disease in HIV-infected patients: conjugate versus polysaccharide vaccine before or after reconstitution of the immune system (CTN-147).

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysac

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Pneumonia in HIV-infected patients in the HAART era: Incidence, risk, and impact of the pneumococcal vaccination

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU631

21 January 2018

Identifiers

10.1093/INFDIS/JIU631

1 reference

Europe PubMed Central

6 October 2017

1 reference

Europe PubMed Central

6 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41662682&oldid=1925658439"